Search results
Peruvian Surf Legend Gabriel Villaran Launches Crowdfunder to Support Brother’s Cancer Treatment
The Inertia via Yahoo News· 11 hours agoGabriel Villaran created a crowdfunder to help pay for treatment of his brother’s diagnosis of ...
STAMP Inhibitor Tops Imatinib, Second-Gen TKIs for Newly Diagnosed CML
MedPage Today· 5 days agoThe STAMP inhibitor asciminib (Scemblix) had a statistically superior response rate compared with...
Novartis study points to larger role for targeted leukemia drug
BioPharma Dive via Yahoo Finance· 5 days agoScemblix “has a nice balance of efficacy and tolerability,” said Odejide. “This is really poised to...
Novartis leukemia drug more effective than older treatments in trial
AOL· 5 days agoSwiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 4 hours agoLive from ASCO 2024 | Oral Report Released Latest Data of Olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3% PR Newswire SUZHOU, China and ROCKVILLE, Md., June 4, 2024 SUZHOU, China ...
Novartis' Oral Drug For Chronic Skin Disease Candidate Shows Efficacy, Long-term Safety - Novartis...
Benzinga· 5 days agoOn Friday, Novartis AG NVS released new data that confirm the long-term efficacy and safety of...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days agoIn honor of National Cancer Survivor Month this June, the St. Baldrick's Foundation, the largest charity funder of childhood cancer research grants, is launching its "Cancer-Free Isn't Free" ...
Rathbones Group PLC Trims Stock Position in Bristol-Myers Squibb (NYSE:BMY)
ETF DAILY NEWS· 1 day agoRathbones Group PLC reduced its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 24.0% in the 4th quarter, according to its most recent 13F filing with the Securities and ...
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI...
Benzinga· 5 days agoREDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting